Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND CODEINE PHOSPHATE vs ROGAINE (FOR WOMEN)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.
Mild to moderate pain,Pain accompanied by fever
FDA-approved: Treatment of female androgenetic alopecia (female pattern hair loss) in women aged 19-49 years with mild to moderate hair loss,Off-label: Treatment of male pattern baldness (off-label for women if used for this purpose), alopecia areata, and other forms of hair thinning
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Apply 1 m L of 2% minoxidil solution topically to the scalp twice daily (total 2 m L per day).
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
The terminal elimination half-life of minoxidil is approximately 4.2 hours (range 2–7 hours) following topical application, but the pharmacodynamic half-life (duration of drug presence in the skin and hair follicle) is longer, estimated at 24 hours. For oral minoxidil, the terminal half-life averages 4.5 hours (range 3–7 hours).
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Minoxidil is primarily metabolized in the liver via glucuronidation to minoxidil glucuronide, which is inactive. Minor metabolism via sulfation may occur. The metabolism is mediated by UDP-glucuronosyltransferases (UGTs).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Renal excretion of unchanged minoxidil and its glucuronide conjugates accounts for approximately 95% of the absorbed dose; about 5% is eliminated unchanged in feces via biliary excretion.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Minoxidil is approximately 20% bound to serum proteins, primarily albumin, with negligible binding to alpha-1-acid glycoprotein.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
The apparent volume of distribution for minoxidil is 3.5 L/kg (range 2.5–4.5 L/kg), indicating extensive extravascular distribution and tissue binding, particularly to vascular smooth muscle.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
Absolute bioavailability of topical minoxidil is approximately 1.5% (range 0.3–3.2%) of the applied dose, due to low percutaneous absorption and extensive first-pass metabolism in the skin. Oral minoxidil has an absolute bioavailability of 90%.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
No dosage adjustment required for hepatic impairment.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Safety and efficacy not established; use is not recommended.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
No specific dose adjustment; use with caution due to potential increased sensitivity.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
None for topical minoxidil (Rogaine for Women). Oral minoxidil (not this formulation) carries a boxed warning for adverse cardiovascular effects.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Systemic absorption can cause cardiovascular effects such as tachycardia, fluid retention, and hypotension (rare with topical use),May cause local skin reactions: irritation, redness, itching, or dryness,Potential for increased hair loss initially (shedding of telogen hairs) during first 2-6 weeks,Avoid contact with eyes, mucous membranes, and broken skin,Use caution in patients with underlying cardiovascular disease (angina, arrhythmias, heart failure),Discontinue if systemic side effects occur or if no improvement after 6 months
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Hypersensitivity to minoxidil or any component of the formulation,Use on broken, irritated, or sunburned scalp,Concomitant use with other topical agents that may increase absorption (e.g., corticosteroids, tretinoin),Relative: Pregnancy and breastfeeding (minoxidil is pregnancy category C; use only if benefit outweighs risk)
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
No clinically significant food interactions. Avoid excessive caffeine or stimulants as they may exacerbate anxiety or palpitations (rare systemic absorption).
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Systemic absorption is minimal (<1.5%) with recommended topical use, but it is classified as pregnancy category C. First trimester: theoretical risk, avoid use. Second and third trimesters: minimal known risk but use only if clearly needed.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Minoxidil is excreted in human milk following oral administration; however, data after topical use are lacking. The milk-to-plasma ratio (M/P) is unknown for topical application. Due to potential for adverse effects in the nursing infant (e.g., hypotension), breastfeeding is not recommended during treatment.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
No dose adjustments are recommended based on pharmacokinetic changes in pregnancy, as systemic absorption is minimal. However, use during pregnancy is generally discouraged. If used, the standard dose (2% or 5% solution, 1 m L twice daily) should not be exceeded.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Minoxidil 5% foam is first-line for female pattern hair loss (FPHL). Response requires 4-6 months of consistent use; counsel patients not to expect immediate results. Initial shedding may occur in first 2-6 weeks due to telogen effluvium; this is a positive sign of drug activity. Discontinue if scalp irritation or hypertrichosis develops. Avoid use on broken or sunburned skin. Apply to dry scalp, not to hair shaft.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
Apply 1/2 capful of foam to dry scalp once daily, no need to rinse.,Results take at least 4 months; continue use to maintain regrowth.,Initial hair shedding is temporary and normal.,Do not use if pregnant or breastfeeding.,Avoid contact with eyes; if contact occurs, rinse with cool water.,Wash hands after application.,Do not use on other body parts.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND CODEINE PHOSPHATE vs ROGAINE (FOR WOMEN), answered by our medical review team.
ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. ROGAINE (FOR WOMEN) is a Hair Growth Agent that works by Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND CODEINE PHOSPHATE and ROGAINE (FOR WOMEN) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of ROGAINE (FOR WOMEN) is: Apply 1 m L of 2% minoxidil solution topically to the scalp twice daily (total 2 m L per day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND CODEINE PHOSPHATE and ROGAINE (FOR WOMEN) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. ROGAINE (FOR WOMEN) is classified as Category C. Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Syste. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.